STOCK TITAN

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Penumbra (NYSE: PEN) has received FDA clearance and launched the Ruby XL System, introducing the market's longest, largest, and softest coil for vascular embolization. The system features three innovative technologies: Ruby XL, POD XL, and Packing Coil XL, all deliverable through a 0.035"+ diagnostic catheter. These coils offer unprecedented volume (up to 40mm size) and extended lengths up to 70 cm, with a primary diameter of .030". The Ruby XL System aims to enhance procedural efficiency, potentially reduce radiation exposure, and optimize outcomes in large vessel and high-flow embolization procedures. The technology includes specialized features like 3D complex shapes for aneurysm framing, hybrid multistage design for targeted vessel control, and innovative liquid metal wave shape technology for dynamic vessel adaptation.
Loading...
Loading translation...

Positive

  • FDA clearance received for innovative Ruby XL System with unique market positioning
  • System offers highest volume per coil in the market, potentially leading to cost savings
  • Enhanced procedural efficiency may reduce radiation exposure for better patient outcomes
  • Expands Penumbra's product portfolio with three new technologies for various clinical applications

Negative

  • None.

News Market Reaction – PEN

+1.19%
1 alert
+1.19% News Effect

On the day this news was published, PEN gained 1.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii.

"We've engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings," said Shruthi Narayan, President of Interventional Business at Penumbra, Inc. "Ruby XL embodies Penumbra's commitment to innovation, delivering mechanical occlusion through more volume without sacrificing softness or deliverability."

The Ruby XL System introduces three unique technologies — Ruby XL, POD® XL, and Packing Coil XL — all of which can be delivered through a 0.035"+ diagnostic catheter. They have a primary diameter of .030" and are designed for procedural efficiency. These coils offer more volume (up to 40mm in size) and are available in extended lengths up to 70 cm.

  • Engineered with a 3D complex shape, Ruby XL coil is designed to frame aneurysms in a variety of clinical applications.
  • POD XL features a hybrid, multistage design and is engineered with three-in-one coil occlusion technology — an anchoring segment, a framing segment, and a dense filling segment. Designed for high flow vessels, POD XL offers smooth delivery and targeted vessel control.
  • Packing Coil XL features an innovative liquid metal wave shape technology, which is designed to adjust dynamically to the size of any vessel (up to 70 cm length).

Penumbra's Ruby portfolio of peripheral embolization products, now with Ruby XL System, provides physicians with one of the most expansive embolization offerings, enabling physicians to have the latest coil technologies and most extensive options for every case. For more information, please visit www.penumbrainc.com/products/ruby-xl.

About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT™), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on InstagramLinkedIn and X.

Important Safety Information
Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/providers. Caution: Federal (USA) law restrictions these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please visit www.peninc.info/risk for the complete IFU Summary Statements.

The clinical results presented herein are for informational purposes only, and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Contact




Jennifer Heth

Parinaz Farzin

Penumbra, Inc.

Merryman Communications

jheth@penumbrainc.com

parinaz@merrymancommunications.com

510-995-9791

310.600.6746


______________________

i Data as of May 2025, Ruby XL System is the largest and longest detachable embolization coil commercially available and the only 035 packing coil commercially available.

ii Ruby XL is 2X larger than Ruby 020 coils and 3X larger than conventional 035 coils. Fewer coils used may potentially lead to reduced radiation exposure.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-introduces-the-ruby-xl-system--the-longest-largest-and-softest-coil-on-the-market-for-vascular-embolization-302473772.html

SOURCE Penumbra, Inc.

FAQ

What are the key features of Penumbra's (PEN) Ruby XL System?

The Ruby XL System features the market's longest, largest, and softest coil for vascular embolization, with coils up to 40mm in size and 70cm in length, deliverable through a 0.035"+ diagnostic catheter.

What is the significance of FDA clearance for Penumbra's (PEN) Ruby XL System?

The FDA clearance allows Penumbra to market the Ruby XL System in the US, offering physicians enhanced efficiency in embolization procedures with potential cost savings and reduced radiation exposure.

How does the Ruby XL System benefit medical procedures?

The system improves procedural efficiency, potentially reduces radiation exposure, and optimizes outcomes in large vessel and high-flow embolization, offering more volume per coil than other market options.

What are the three technologies included in Penumbra's Ruby XL System?

The system includes Ruby XL with 3D complex shape for aneurysm framing, POD XL with hybrid multistage design, and Packing Coil XL with liquid metal wave shape technology.

What is the delivery mechanism for Penumbra's Ruby XL System coils?

All three technologies in the Ruby XL System can be delivered through a 0.035"+ diagnostic catheter with a primary diameter of .030".
Penumbra Inc

NYSE:PEN

PEN Rankings

PEN Latest News

PEN Latest SEC Filings

PEN Stock Data

13.51B
37.52M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ALAMEDA